Immatics N.V. (IMTX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Harpreet Singh Ph.D.
|
CEO, MD, Member of Management Board & Executive Director | 970.63k | -- | 1975 |
|
Dr. Venkat Ramanan Ph.D.
|
Chief Financial Officer | -- | -- | 1970 |
|
Ms. Amie Krause
|
Chief People Officer | -- | -- | 1973 |
|
Dr. Hans-Georg Rammensee Ph.D.
|
Co-Founder & Member of the Scientific Advisory Board | -- | -- | -- |
|
Dr. Toni Weinschenk Ph.D.
|
Co-Founder & Chief Innovation Officer | -- | -- | 1970 |
|
Mr. Steffen Walter Ph.D.
|
Chief Operations Officer | -- | -- | 1977 |
|
Mr. Ephraim Hofsäß M.Sc.
|
Vice President of SEC Reporting & Accounting | -- | -- | -- |
|
Mr. James Pepin J.D.
|
General Counsel & Corporate Secretary | -- | -- | -- |
|
Ms. Lauren Schroeder
|
Vice President of Marketing | -- | -- | -- |
|
Dr. Carsten Reinhardt M.D., Ph.D.
|
Chief Development Officer | -- | -- | 1967 |
Immatics N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 704
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Corporate Governance
Upcoming Events
November 17, 2026 at 1:30 PM UTC
Immatics N.V. Earnings Date
